Wells Fargo & Company Electro Core, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.21 - $0.36 $2 - $3	11 Added 0.22%	5,104 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $0.68 $0 - $1	-2 Reduced 0.04%	5,093 $2,000
Q2 2022 Aug 12, 2022	SELL	$0.27 - $0.61 $179 - $405	-665 Reduced 11.55%	5,095 $2,000
Q1 2022 May 16, 2022	SELL	$0.5 - $0.88 $84 - $148	-169 Reduced 2.85%	5,760 $3,000
Q4 2021 Feb 14, 2022	SELL	$0.58 - $1.09 $17,395 - $32,692	-29,993 Reduced 83.49%	5,929 $3,000

Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.18 $114 - $145	123 Added 0.34%	35,922 $41,000
Q2 2021 Aug 16, 2021	BUY	$1.19 - $2.06 $16 - $28	14 Added 0.04%	35,799 $43,000
Q1 2021 May 13, 2021	SELL	$1.62 - $3.05 $4,861 - $9,153	-3,001 Reduced 7.74%	35,785 $73,000
Q4 2020 Feb 09, 2021	BUY	$1.44 - $1.98 $3,817 - $5,248	2,651 Added 7.34%	38,786 $60,000
Q3 2020 Nov 05, 2020	BUY	$0.8 - $2.33 $3,676 - $10,706	4,595 Added 14.57%	36,135 $63,000
Q2 2020 Aug 13, 2020	SELL	$0.75 - $1.29 $51,879 - $89,231	-69,172 Reduced 68.68%	31,540 $26,000
Q1 2020 May 14, 2020	BUY	$0.33 - $1.62 $33,234 - $163,153	100,712 New	100,712 $96,000

143K

Ticker ECOR
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 71,176,896
Market Cap $445M
Description
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults....

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.